Veeva Systems Inc. advanced 8.1% in after-hours trading after reporting fiscal second-quarter 2027 results that exceeded expectations and included new customer commitments from Biogen Inc. and Regeneron Pharmaceuticals Inc.
The life sciences cloud software provider posted subscription revenue of $766.8 million, a 16% increase from the same quarter a year ago. Veeva also topped earnings-per-share estimates for the fourth consecutive quarter, with adjusted EPS of $2.24 compared with the $2.14 consensus, according to the data.
The company’s shares reached $264.79 in after-hours trading, extending gains from a 52-week range of $148.05 to $310.50. For context, major U.S. equity benchmarks showed modest gains during regular trading, with the S&P 500 up 0.1%, the Nasdaq gaining 0.2%, and the Dow rising 0.3%.
Analysts responded positively to the results. Piper Sandler initiated coverage with an Overweight rating and raised its price target to $314.71, up from the prior consensus target. The firm cited Veeva’s sustained revenue growth and expanding customer base in the life sciences sector as key drivers of the upgrade.
The earnings release coincided with new business announcements. Biogen and Regeneron disclosed global commitments to deploy Veeva’s Vault CRM platform, signaling continued adoption of the company’s cloud-based solutions among leading biopharmaceutical firms.
